Entrada Therapeutics, Inc.
TRDA
NASDAQ·Healthcare·Biotechnology·Mkt cap $283.4M
$7.17
▼ -1.78%
P/E
-1.81
Mkt Cap
$283.4M
52-Wk Range
$5.02–$16.45
52-Week Range
$5.02 - $16.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 37.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary endosomal escape vehicle platform enabling intracellular drug delivery
- Versatile technology applicable across multiple therapeutic modalities and disease targets
- First-mover advantage in EEV-based treatment of neuromuscular diseases
- Focused pipeline targeting high-unmet-need rare genetic disorders
Bear Case
1 risk
- Low volatility (beta -0.3).
Growth
Strong growth ahead
Clinical advancement of ENTR-601-44 for DMD and DM1 indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+10.9% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying TRDA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$1.01 vs -$0.97 consensus (-3.7% surprise). Revenue of $898.0K vs $2.2M expected (-59.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-3.7%
Revenue trend · last 8Q
—
-11%
-65%
-98%
-92%
-97%
-96%
-54%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$19.6M
$37.4M
$20.6M
$1.9M
$1.6M
$1.3M
$875.0K
$898.0K
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-4762.0%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Aug 12, 2026
vs Industry
How TRDA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related